Olanzapine

Sedona inpatient program emphasizes due diligence, withdrawal-aware care, and holistic alternatives for depression and anxiety support Many individuals experience side effects, emotional destabilization, or difficulty stopping. We want people to have a fuller picture—and safer support options.” — Alternative to Meds Center SEDONA, AZ, UNITED STATES, March 8, 2026 / EINPresswire.com / -- Alternative to Meds Center (ATMC) is increasing public education about Prozac (fluoxetine), including its approved uses, potential risks, withdrawal considerations, and the importance of informed decision-making when starting or stopping SSRI antidepressants. With Prozac remaining one of the most commonly prescribed medications for depression and anxiety-related conditions, ATMC encourages individuals and families to practice due diligence and seek qualified guidance—particularly when medication reduction or discontinuation is being considered. Prozac is FDA-approved for several psychiatric indications, including major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder. Fluoxetine is also approved for acute depressive episodes in bipolar conditions and for “treatment-resistant depression” when prescribed in combination with olanzapine, an antipsychotic medication—typically after multiple antidepressant trials have not produced adequate results. “Marketing often frames Prozac as a straightforward path back to happiness and productivity,” said a representative of Alternative to Meds Center. “But many individuals experience side effects, emotional destabilization, or difficulty stopping. We want people to have a fuller picture—and safer support options—before they begin, change, or discontinue SSRIs.” Due Diligence Matters—Especially With Long-Term Use ATMC notes that many patients assume their prescriber will fully explain medication risks, withdrawal realities, and non-drug alternatives. However, individuals may not receive comprehensive guidance about potential adverse reactions, drug-drug interactions, or the challenges associated with SSRI discontinuation—particularly after long-term use. ATMC reports extensive clinical experience helping clients taper and withdraw from antidepressants and other psychiatric medications. The center also emphasizes that many people benefit from combining gradual tapering with non-toxic, whole-person supports aimed at improving sleep, mood stability, and overall physical resilience. Understanding SSRIs and Serotonin-Related Concerns Fluoxetine is classified as a selective serotonin reuptake inhibitor (SSRI), designed to alter serotonin signaling. Serotonin is a naturally occurring neurotransmitter with wide-ranging influence throughout the body, affecting not only mood but also digestion, sleep, metabolic function, and numerous regulatory processes. ATMC emphasizes that no medication “creates” serotonin; instead, SSRIs manipulate neurotransmitter transmission. The center also notes that the serotonin-based explanation for depression has been a subject of ongoing scientific debate, with some researchers questioning whether serotonin levels are a primary cause of depression or a downstream effect influenced by multiple biological and environmental factors. Serotonin Syndrome Awareness and Medication Interactions ATMC highlights the need for public awareness of serotonin syndrome, a potentially life-threatening toxicity state that can occur when serotonin activity becomes excessive—particularly when multiple serotonergic agents are combined, when doses are changed, or in overdose scenarios. The center urges individuals to seek immediate medical care if severe symptoms emerge, and to avoid combining serotonergic supplements or medications without medical direction. The center also notes that certain combinations—such as mixing SSRIs with MAOIs or other serotonergic agents—can elevate risk, making careful medication reconciliation and monitoring essential. Prozac Risks, Side Effects, and Black Box Warnings Like other SSRIs, Prozac may produce side effects that range from mild to severe. Commonly reported issues include nausea, sleep disruption, fatigue, and increased anxiety—particularly early in treatment. Some individuals report agitation, akathisia, mood volatility, hostility, tremors, and sexual dysfunction. Prozac also carries a black box warning related to increased suicidal thoughts in some younger populations, underscoring the importance of close monitoring during initiation or dose changes. ATMC encourages individuals to report emergent suicidality, extreme agitation, confusion, or other alarming reactions to a medical professional without delay. Withdrawal Considerations and the Importance of Gradual Reduction Although Prozac’s metabolite has a long half-life—meaning it can remain active in the body for an extended period—ATMC emphasizes that gradual tapering is still commonly advised to reduce unnecessary discomfort and to minimize destabilization. The center notes that a longer half-life does not eliminate the possibility of withdrawal symptoms, which may include dizziness, digestive issues, flu-like symptoms, sleep disturbance, and mood disruption. ATMC also cautions that medication switching—especially within the SSRI class—should be handled carefully to avoid dangerous drug-drug interactions while fluoxetine remains in the bloodstream. Prozac, Zoloft, Luvox—Similar Class, Different Impacts ATMC notes that Prozac (fluoxetine), Zoloft (sertraline), and Luvox (fluvoxamine) are often spoken about interchangeably because they share the SSRI classification. However, each has a different active ingredient and may affect individuals differently—including differences in side effect profiles, withdrawal patterns, and interaction risks. ATMC encourages patients to apply the same level of critical thinking and careful oversight to each medication decision, even when drugs appear “similar” by category. Holistic Alternatives and Inpatient Support Alternative to Meds Center provides inpatient programs designed for individuals seeking medically supervised tapering alongside integrative therapies and lifestyle-based alternatives. ATMC’s model is focused on addressing underlying contributors to symptoms—such as sleep disruption, nutritional imbalance, toxin exposure burden, chronic stress load, and microbiome health—rather than relying solely on medication-based symptom suppression. “Our goal is to help clients stabilize safely,” the ATMC representative added. “That includes careful tapering protocols when appropriate, education, and holistic supports that empower long-term well-being without ongoing dependence on prescriptions.” For more information about Alternative to Meds Center’s Prozac tapering support, antidepressant withdrawal programs, and holistic mental wellness options, contact the admissions team. Alternative to Meds Center Alternative to Meds Center +1 877-503-0770 email us here Visit us on social media: LinkedIn Instagram Facebook YouTube TikTok X Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations 1 Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological conditions as it drives forward its Pivot to Growth strategy PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence and help patients maintain long-term stability, with the goal of addressing a critical treatment gap for people living with schizophrenia. Currently, there is no long-acting olanzapine formulation without an FDA-required Risk Evaluation and Mitigation Strategy (REMS), which mandates administration in a certified healthcare facility and requires a 3-hour post-injection monitoring period. In the Phase 3 SOLARIS trial, TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety pro with currently available olanzapine formulations and showed no evidence for the need for post-injection monitoring. “Treatment adherence remains a major challenge and unmet need for people living with schizophrenia, including many who rely on oral forms of olanzapine. TEV-'749, our investigational subcutaneously delivered olanzapine LAI, has the potential to help provide stability by offering the proven efficacy and safety of olanzapine as a once-monthly treatment,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “For too long, the lack of a viable long-acting olanzapine formulation has limited the options available to these individuals, and we look forward to working with the FDA on the review of this NDA for TEV-'749 to help address this gap in care.” “Daily olanzapine is one of the most widely prescribed antipsychotics for people living with schizophrenia, and this long‑acting formulation may better fit into their lives,” said Christophe Douat, CEO of Medincell. “As experience with long‑acting injectables continues to grow, they are increasingly recognized as an important treatment option in serious psychiatric conditions. The potential reach of a practical long‑acting option is significant.” The NDA for TEV-'749 is based on results from the Phase 3 SOLARIS trial, including Week 56 results studying its efficacy, safety and tolerability in participants aged 18 to 64 living with schizophrenia. 1 The results demonstrated an efficacy and safety pro with currently available olanzapine formulations. 1 TEV-'749 is an investigational once-monthly subcutaneous LAI of the second-generation atypical antipsychotic olanzapine. It is not approved by any regulatory authority for any use at this time. TEV-'749 utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that provides a controlled steady, sustained release of olanzapine. About Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS) SOLARIS is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of olanzapine extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 18-64 years) with schizophrenia. 1 For period one of the study (first 8 weeks), 675 patients were randomized to receive a subcutaneous injection of once-monthly olanzapine LAI (TEV-'749) (low, medium or high dose) or placebo in a 1:1:1:1 ratio. 1 For period two (next 48 weeks), patients who completed period one were randomized and equally allocated to one of the three olanzapine LAI (TEV-'749) treatment groups. 1 The end-of-treatment and follow-up visits were 4 and 8 weeks after administration of the last treatment dose, respectively. 1 The primary objective of the Phase 3 SOLARIS study was to evaluate the efficacy of olanzapine LAI (TEV-'749) in adult patients with schizophrenia. 1 A key secondary objective was to further evaluate the efficacy of olanzapine LAI (TEV-'749) based on additional parameters in adult patients with schizophrenia. 1 A secondary objective of period two of the study was to evaluate the safety and tolerability of olanzapine LAI (TEV-'749) in adult patients with schizophrenia. 1 About Schizophrenia Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts. 2 Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability. 2,3,4 Approximately 1% of the world’s population will develop schizophrenia in their lifetime, and 3.5 million people in the U.S. are currently diagnosed with the condition. 3 , 4 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women. 4 The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization. 4 Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology. 5,6,7 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations. 2,3,4,5,6,7 About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit Cautionary Note Regarding Forward-Looking Statements This Press Release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop olanzapine LAI (TEV-‘749) for the treatment of adult patients diagnosed with schizophrenia and to obtain regulatory FDA approval; our ability to successfully compete in the marketplace, including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. Substance Abuse and Mental Health Services Administration. Schizophrenia. . Accessed February 2026. Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and Reduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl), S62–S68. Emsley, R., & Kilian, S. (2018). Efficacy and safety pro paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14, 205–223. Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50. Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The Am J Psychiatry, 170(6), 609–615. Teva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations Inquires TevaIR@Tevapharm.com About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. Contact: communication@medincell.com